Stem Cell Theranostics is a privately held biotech company based out of Redwood City, California that provides drug companies with a method to more accurately predict cardiotoxicity and cardiovascular drug efficacy.[1]
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Headquarters | , |
History
editStem Cell Theranostics was one of the first med tech startup to come out of the StartX incubator program. The company uses technology developed at Stanford,[2][3] to create a "clinical trial in a dish" drug screening platform, which reduces the risk of drug development.[4] The company currently works with drug discovery and biotechnology companies to use patient-specific induced pluripotent stem cells for development of novel therapeutics.[5]
References
edit- ^ Deanna Pogorelc. "Merck and J&J back StartX; "clinical-trial-in-a-dish" biotech wows at Demo Day". MedCity News. Retrieved 11 November 2014.
- ^ Krista Conger. "Scientists show that lab-made heart cells can be ideal model for disease research, drug testing". News Center. Retrieved 11 November 2014.
- ^ Krista Conger. "Researchers use stem cells to pinpoint cause of common type of sudden cardiac death". News Center. Retrieved 11 November 2014.
- ^ "Stem Cell Theranostics' clinical trial in a dish". Silicon Valley Business Journal. 29 March 2013. Retrieved 11 November 2014.
- ^ "The Experiment Begins: Y Combinator Admits First Biotech Startups". Xconomy. Retrieved 11 November 2014.
